# Immunis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunis

- Industry: Biotechnology
- Headquarters: Irvine, US
- Website: www.immunisbiomedical.com
- Total disclosed funding: $29M
- Latest round: Series A (Oct 24, 2024)
- Investors on record: 5

## About

Based in California and founded in 2019, Immunis, Inc. operates as a biotechnology company providing treatment for age- and disease-related immune decline. In June 2024, Immunis, Inc. raised USD 20.4 million in venture funding from returning investors Remiges Ventures, Continuum Health Ventures, BOLD Capital Partners, with participation from new investors LifeSpan Vision Ventures and JLS Fund. Other unspecified investors also participated in the round. As of 2023, the chief science officer is Tom Lane, and the chairman is Hans S. Keirstead of the company. Immunis provides a technology known as a steam, which is a novel method to grow human stem cells for clinical use in improving immune system development, modulation, and health. The company’s technology is used for treating muscle atrophy, metabolic and vascular function, and tissue inflammation in the human body. As of 2023, the company serves industries such as biotechnology, pharmaceuticals, healthcare, and applied science. The company will use the June 2024 funding to support two Phase 2 clinical trials of IMM01-STEM aimed at treating muscle loss and metabolic dysfunction in elderly populations.

## Funding rounds

- Series A, Oct 24, 2024, $4.6M — Remiges Ventures, BOLD Capital Partners, JLS Fund, Continuum Health Ventures, LifeSpan Vision Ventures
- Series A, Jun 17, 2024, $16M — Remiges Ventures, BOLD Capital Partners, JLS Fund, Continuum Health Ventures, LifeSpan Vision Ventures
- Series A, May 31, 2022, $8.4M — Remiges Ventures

## Investors

- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A
- JLS Fund (https://capitalatlas.ai/funds/jls-fund) — Series A
- Continuum Health Ventures (https://capitalatlas.ai/funds/continuum-health-ventures) — Series A
- LifeSpan Vision Ventures (https://capitalatlas.ai/funds/lifespan-vision-ventures) — Series A